Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug shows promise for teens with stubborn hives

NCT ID NCT03437278

Completed Symptom relief Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called ligelizumab in 49 teenagers aged 12 to 17 who had chronic hives (itchy welts) that didn't get better with standard allergy pills. The goal was to see if adding ligelizumab to their current treatment could reduce the number and severity of hives. Participants received either the study drug or a placebo, and their symptoms were tracked over several weeks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic idiopathic urticaria Chronic Urticaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC SPONTANEOUS URTICARIA

Contacts and locations

Locations

  • Novartis Investigative Site

    Rosario, Santa Fe Province, S2000BRH, Argentina

  • Novartis Investigative Site

    Bahía Blanca, B8000JRB, Argentina

  • Novartis Investigative Site

    Buenos Aires, C1125ABE, Argentina

  • Novartis Investigative Site

    Brussels, 1200, Belgium

  • Novartis Investigative Site

    Montreal, Quebec, H3H 1P3, Canada

  • Novartis Investigative Site

    Québec, Quebec, G1V 4W2, Canada

  • Novartis Investigative Site

    Berlin, 13353, Germany

  • Novartis Investigative Site

    Mainz, 55131, Germany

  • Novartis Investigative Site

    Budapest, HUN, 1037, Hungary

  • Novartis Investigative Site

    Nashik, Maharashtra, 422 101, India

  • Novartis Investigative Site

    New Delhi, National Capital Territory of Delhi, 110 060, India

  • Novartis Investigative Site

    Bikaner, Rajasthan, 334001, India

  • Novartis Investigative Site

    Saint Petersburg, 191015, Russia

  • Novartis Investigative Site

    Saint Petersburg, 191123, Russia

  • Novartis Investigative Site

    Smolensk, 214019, Russia

  • Novartis Investigative Site

    Barcelona, Barcelona, 08006, Spain

  • Novartis Investigative Site

    Esplugues de Llobregat, Barcelona, 08950, Spain

  • Novartis Investigative Site

    Taipei, Taiwan, 10002, Taiwan

  • Novartis Investigative Site

    Aydin, Turkey, 09100, Turkey (Türkiye)

  • Novartis Investigative Site

    Ankara, 06100, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.